Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients

References

• Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006;24:2673–8.10.1200/JCO.2005.05.3025
   PubMed Web of Science ®Google Scholar
• Vander Poorten V, Hunt J, Bradley PJ, Haigentz M, Jr., Rinaldo A, Mendenhall WM, et al. Recent trends in the management of minor salivary gland carcinoma. Head Neck 2014; 36(3): 444–55.10.1002/hed.v36.3
   PubMed Web of Science ®Google Scholar
• Vander Poorten VL. Hart AA, van der Laan BF, Baatenburg de Jong RJ, Manni JJ, Marres HA, et al. Prognostic index for patients with parotid carcinoma: external validation using the nationwide 1985–1994 dutch head and neck oncology cooperative group database. Cancer. 2003;97(6):1453–63.10.1002/(ISSN)1097-0142
   PubMed Web of Science ®Google Scholar
• Eveson JW, Auclair P, Gnepp DR, El-Naggar AK. Tumours of the salivary glands. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. Pathology and genetics of head and neck tumours. Lyon: IARC Press; 2005. p. 210. World Health Organization Classification of Tumours; vol 9.
   Google Scholar
• Kaplan MJ, Johns ME, Cantrell RW. Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg. 1986;95:165–70.10.1177/019459988609500206
   PubMed Web of Science ®Google Scholar
• Alberts DS, Manning MR, Coulthard SW, Koopmann CF Jr, Herman TS. Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer. 1981;47:645–8.10.1002/(ISSN)1097-0142
   PubMed Web of Science ®Google Scholar
• Dreyfuss AI, Clark JR, Fallon BG, Posner MR, Norris CM Jr, Miller D. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer. 1987;60:2869–72.10.1002/(ISSN)1097-0142
   PubMed Web of Science ®Google Scholar
• Creagan ET, Woods JE, Rubin J, Schaid DJ. Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Cancer. 1988;62:2313–9.10.1002/(ISSN)1097-0142
   PubMed Web of Science ®Google Scholar
• Licitra L, Cavina R, Grandi C, Palma SD, Guzzo M, Demicheli R, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma: A phase II trial of 22 patients. Ann Oncol. 1996;7:640–642.10.1093/oxfordjournals.annonc.a010684
   PubMed Web of Science ®Google Scholar
• Debaere D, Vander Poorten V, Nuyts S, Hauben E, Schoenaers J, Schöffski P, et al. Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer. B-ENT. 2011;7(1):1–6.
   PubMed Web of Science ®Google Scholar
• Lagha A, Chraiet N, Ayadi M, Krimi S, Allani B, Rifi H, et al. Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head Neck Oncol. 2012 May 4;4:19.10.1186/1758-3284-4-19
   PubMedGoogle Scholar
• Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar A, Kies M, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004;10(3):944–946.10.1158/1078-0432.CCR-03-0253
   PubMed Web of Science ®Google Scholar
• Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 1994;54:5675–82.
   PubMed Web of Science ®Google Scholar
• Nashed M, Casasola RJ. Biological therapy of salivary duct carcinoma. J Laryngol Otol. 2009 Feb;123(2):250–2.10.1017/S0022215108002314
   PubMed Web of Science ®Google Scholar
• Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003;39(7):724–727.10.1016/S1368-8375(03)00097-6
   PubMed Web of Science ®Google Scholar
• Krishnamurthy J, Krishnamurty DM, Baker JJ, Zhen W, Lydiatt D, Ganti AK. Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature. Head Neck. 2013 Dec;35(12):E372–5.10.1002/hed.23307
   Google Scholar
• Perissinotti AJ, Lee Pierce M, Pace MB, El-Naggar A, Kies MS, Kupferman M. The role of trastuzumab in the management of salivary ductal carcinomas. Anticancer Res. 2013 Jun;33(6):2587–91.
   PubMed Web of Science ®Google Scholar
• Limaye SA, Posner MR, Krane JF, Fonfria M, Lorch JH, Dillon DA, et al. Trastuzumab for the treatment of salivary duct carcinoma. Oncologist. 2013;18(3):294–300.10.1634/theoncologist.2012-0369
   PubMed Web of Science ®Google Scholar
• Kaidar-Person O, Billan S, Kuten A. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Med Oncol. 2012 Jun;29(2):704–6.10.1007/s12032-011-9884-1
   PubMed Web of Science ®Google Scholar
• Vattemi E, Graiff C, Sava T, Pedersini R, Caldara A, Mandarà M. Systemic therapies for recurrent and/or metastatic salivary gland cancers. Expert Rev Anticancer Ther. 2008 Mar;8(3):393–402.10.1586/14737140.8.3.393
   PubMed Web of Science ®Google Scholar
• Prat A, Parera M, Reyes V, Peralta S, Cedrés S, Andreu J, et al. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck. 2008 May;30(5):680–3.10.1002/(ISSN)1097-0347
   PubMed Web of Science ®Google Scholar
• Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck. 2007 Oct;29(10):907–12.10.1002/(ISSN)1097-0347
   PubMed Web of Science ®Google Scholar
• Locati LD, Rinaldi G, Bossi P, Dagrada GP, Quattrone P, Cantú G, et al. Herceptin® plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncol. 2005 Jan;41(1):97–8.10.1016/j.oraloncology.2004.03.002
   PubMed Web of Science ®Google Scholar
• Dori S, Vered M, David R, Buchner A. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. J Oral Pathol Med. 2002 Sep;31(8):463–7.10.1034/j.1600-0714.2002.00017.x
   PubMed Web of Science ®Google Scholar
• Skálová A, Stárek I, Kucerová V, Szépe P, Plank L. Salivary duct carcinoma – a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol Res Pract. 2001;197(9):621–6.10.1078/0344-0338-00136
   PubMed Web of Science ®Google Scholar
• Jaspers HC, Verbist BM, Schoffelen R, Mattijssen V, Slootweg PJ, van der Graaf WT, et al. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol. 2011 Jun 1;29(16):e473–6.10.1200/JCO.2010.32.8351
   Google Scholar